Akums demonstrates clinical versatility of Lacosamide in epilepsy care

Clinical evidence has consistently highlighted lacosamide’s efficacy and safety.

Akums Drugs & Pharmaceuticals reaffirmed the clinical importance of lacosamide, a well-established antiepileptic drug (AED), as a versatile and effective treatment option for patients across diverse epilepsy populations and clinical settings.

“With lacosamide, we continue our mission to support patient-centric care in neurology,” said Sanjeev Jain, MD, Akums Drugs & Pharmaceuticals. “Its flexible dosing options and multiple formulations address critical unmet needs in epilepsy management, ensuring therapy continuity whether at home or in hospital settings. This reflects our broader CNS portfolio strategy and commitment to improving patient outcomes.”

Clinical evidence has consistently highlighted lacosamide’s efficacy and safety. Long-term studies demonstrate sustained seizure control for up to five years with favorable tolerability. In pediatric refractory epilepsy, including children under four years of age, lacosamide has shown effective seizure reduction and good safety outcomes. Intravenous formulations have proven particularly valuable in urgent care, managing acute repetitive seizures and convulsive status epilepticus in critically ill children.

Unlike traditional sodium channel blockers that target fast inactivation, lacosamide uniquely enhances the slow inactivation of voltage-gated sodium channels. This mechanism stabilizes hyperexcitable neuronal membranes while preserving normal physiological activity, reducing cognitive and systemic side effects and minimizing drug–drug interactions.

Lacosamide’s clinical benefits extend to patients with comorbid conditions. Research indicates efficacy comparable to carbamazepine-CR in individuals with psychiatric comorbidities, while supporting quality of life in vulnerable groups, including people who inject drugs. In post-stroke epilepsy patients receiving oral anticoagulants, lacosamide has demonstrated long-term safety and effectiveness as an adjunct therapy. Compared with alternatives such as perampanel, it offers a more favorable safety profile, making it a reliable option for sensitive populations, including pregnant women.

According to Dr. Pooja Anand, Consultant Neurologist at Paras Health Gurugram, “Lacosamide has proven to be a reliable option for both adjunctive and monotherapy use. Its favorable tolerability and flexible administration improve adherence and minimize therapy interruptions, which are critical for long-term seizure control and patient quality of life.”

Lacosamide has been a cornerstone of Akums’ CNS portfolio for many years. Its flexible dosing, broad applicability, and multiple delivery routes support adherence, optimize outcomes, and align with modern healthcare needs.

With the high prevalence of epilepsy in India and worldwide, lacosamide stands out as a clinically robust, well-tolerated, and patient-friendly therapy. Its proven efficacy, safety, and versatility make it a trusted choice for healthcare providers seeking reliable, individualized long-term management of epilepsy.